Benefit of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery
The Evaluation of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years old
- Patients scheduled for any type of nail surgical procedure
- Willingness to participate in the study
- Ability to understand all instructions in the English language
Exclusion Criteria:
- Failure to have nail surgery performed
- Likely inability to comply with the study protocol or cooperate fully with the research team
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hydrophilic polymer and potassium ferrate powder
Hydrophilic polymer with potassium ferrate powder is applied to the surgical wound with pressure until hemostasis is achieved
|
Application with pressure until hemostasis is achieved
|
|
No Intervention: Direct pressure with sterile gauze
Direct pressure with sterile gauze is applied to the surgical wound until hemostasis is achieved
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time (in seconds) to bleeding cessation with hydrophilic polymer and potassium ferrate; time (in seconds) to bleeding cessation with direct pressure with sterile gauze
Time Frame: Baseline
|
Time (in seconds) will be measured from application of intervention/nonintervention until bleeding cessation
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with at least one adverse event
Time Frame: End of study (28 days)
|
Adverse events will only include those that are determined to be related to the study device
|
End of study (28 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-02021562
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nail Diseases
-
NCT07388823Not yet recruitingNail Bed Injury | Nail Laceration | Nail Plate Disruption
-
NCT00641433Unknown
-
NCT07041047CompletedIngrown Toenails | Ingrown Nail Inflammation
-
NCT05100680Completed
-
NCT03263624Unknown
-
NCT03991936CompletedNail Diseases | Nail Psoriasis
-
NCT07313072Not yet recruiting
Clinical Trials on Hydrophilic polymer and potassium ferrate powder
-
NCT03028025CompletedCardiovascular Diseases | Coronary Artery Disease | Atherosclerosis | Angina Pectoris | Arterial Occlusion | Hematoma | Anticoagulant-Induced Bleeding
-
NCT05637970CompletedCardiovascular Diseases | Arterial Occlusion | Hematoma
-
NCT05468957WithdrawnCardiovascular Diseases | Atherosclerosis | Arterial Occlusion | Hematoma
-
NCT06835829Recruiting
-
NCT02653560Completed
-
NCT04867291Not yet recruitingIodine Bioavailability
-
NCT01682837Completed
-
NCT04048616CompletedMuscle Loss | Age-Related Sarcopenia
-
NCT06819111Not yet recruiting
-
NCT03323372Completed